BIO 021Alternative Names: BIO021
Latest Information Update: 02 Mar 2010
At a glance
- Originator Gardant Pharmaceuticals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Acne
Most Recent Events
- 04 Jan 2007 Gardant Pharmaceuticals has been acquired by Switch Pharma
- 22 Oct 2005 Phase-I clinical trials in Acne in USA (unspecified route)